Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved docetaxel in combination with carboplatin, trastuzumab (s/c), and pertuzumab (tch(s/c)p) therapy for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence in adult patients.
This is written in the approval document as:
Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.
Citation
DOCEtaxel, CARBOplatin, Trastuzumab (S/C) and Pertuzumab (TCH(S/C)P) Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/731-docetaxel-carboplatin-trastuzumab-s-c-and-pertuzumab-tch-s-c-p-therapy.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Carboplatin, Docetaxel, Pertuzumab, Trastuzumab |